Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Terminated 2Withdrawn 1Unknown 1Suspended 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Uveal Melanoma 2Melanoma 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

venetoclax 6zanubrutinib 3tafasitamab 2obinutuzumab 2acalabrutinib 2Specimen Handling 2Rituximab 2Biopsy 2resiniferatoxin 1pirtobrutinib 1fludarabine 1duvelisib 1Therapeutics 1Sirolimus 1Prednisone 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunoglobulins 1Exercise 1Everolimus 1Disulfides 1Cyclophosphamide 1Blood Cell Count 1Biopsy, Needle 1Bendamustine Hydrochloride 1Azacitidine 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Interleukin-2 × Clear all
NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center

Phase 1 Not yet recruiting
15 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡